Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for GSK plc (GSK) provides access to the company’s regulatory disclosures as a foreign private issuer. GSK files an annual report on Form 20-F and frequent current reports on Form 6-K under the Securities Exchange Act of 1934. These documents, together with information on American Depositary Shares listed on the New York Stock Exchange, form a key source of official information for investors analyzing GSK stock.
Recent Form 6-K filings include multiple transaction notifications for persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. These reports detail acquisitions of ordinary shares or American Depositary Shares, often through dividend reinvestment plans, share reward plans or the exercise of options under GSK’s share save arrangements, and specify trade dates, prices, volumes and trading venues such as the London Stock Exchange and New York Stock Exchange.
Other 6-K filings report total voting rights, including the number of issued ordinary shares, treasury shares and the resulting total voting rights figure. This information helps shareholders determine whether they must notify changes in their holdings under applicable disclosure rules. Additional 6-K submissions incorporate press releases on significant product approvals, clinical trial results and agreements, such as approvals for Exdensur (depemokimab), Nucala (mepolizumab) in COPD, Shingrix prefilled syringe presentations, and positive phase III results for bepirovirsen in chronic hepatitis B.
On Stock Titan, these filings are complemented by AI-powered summaries that explain the practical meaning of each document. Investors can quickly understand insider dealing reports, changes in capital structure, and major regulatory or clinical events without reading every line of the original filing. Real-time updates from EDGAR ensure that new GSK 6-K submissions, as well as the annual 20-F, appear promptly, while insider transactions analogous to Form 4 in the US domestic context are captured through the PDMR transaction notifications.
By using this page, users can review GSK’s historical and current SEC filings, track patterns in executive and director share dealings, and connect clinical and regulatory announcements to their formal disclosure record, all with the support of AI-generated explanations.
GSK plc reports that on 15 April 2026 it repurchased 325,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. The shares were bought at prices between 2,142.00p and 2,201.00p with a volume-weighted average price of 2,179.65p per share and will be held as Treasury shares.
The purchases were made under a non-discretionary agreement with the broker announced on 17 February 2026, since when GSK has repurchased 19,196,521 ordinary shares. After this transaction, GSK holds 259,087,615 shares in treasury and has 4,057,103,154 ordinary shares in issue, which is also the total number of voting rights.
GSK confirms that, in line with DTR 5.5.1R, the voting rights attributable to the ordinary shares held in treasury represent 6.39%. Detailed schedules list the quantities and prices executed across trading venues BATE, CHIX and XLON as part of the buyback activity.
GSK plc has completed its acquisition of 35Pharma Inc., a private, Canada-based clinical-stage biopharma company, for $950 million. The deal brings HS235, a potential best-in-class therapy targeting the activin receptor signalling pathway for pulmonary hypertension (PH), into GSK’s respiratory, immunology and inflammation pipeline.
HS235 is designed with enhanced selectivity intended to reduce bleeding and other adverse events seen with current pulmonary arterial hypertension treatments, and early studies have suggested possible metabolic benefits such as fat-selective weight loss and improved insulin sensitivity. GSK highlights that PH affects about 82 million people worldwide with limited treatment options and around 50% five-year survival, and plans to start proof-of-concept trials in pulmonary arterial hypertension and PH due to heart failure with preserved ejection fraction imminently.
GSK plc reports that, acting through BNP Paribas, it repurchased 325,000 ordinary shares on 14 April 2026 under its existing share buyback programme. The shares, with a nominal value of 31¼ pence each, were bought at prices between 2,164.00p and 2,194.00p, with a volume‑weighted average price of 2,176.46p per share.
The repurchased shares will be held as Treasury shares. Since 17 February 2026, GSK has bought back a total of 18,871,521 ordinary shares. After this transaction, the company holds 258,762,615 ordinary shares in treasury and has 4,057,428,154 ordinary shares in issue, which is also the total number of voting rights.
GSK notes that, in line with DTR 5.5.1R, 6.38% of its voting rights are now represented by ordinary shares held in treasury. The filing also provides detailed trade-by-trade disclosure across London Stock Exchange and CBOE Europe venues as part of the programme.
GSK plc reports that, acting through BNP Paribas, it repurchased 325,000 ordinary shares of 31¼ pence each on 13 April 2026 at prices between 2,154.00p and 2,180.00p, with a volume‑weighted average price of 2,169.64p.
The shares will be held as Treasury shares as part of GSK’s existing share buyback programme under a non‑discretionary agreement with the broker announced on 17 February 2026. Since that date, GSK has repurchased 18,546,521 ordinary shares.
After this transaction, GSK holds 258,437,615 ordinary shares in treasury and has 4,057,753,154 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.37% of the company’s voting rights.
GSK plc reported that several senior executives and persons closely associated with them acquired small amounts of GSK ordinary shares through dividend reinvestment. The transactions reflect dividends paid on 9 April 2026 being automatically used to buy additional shares in investment accounts.
On the London Stock Exchange, shares were acquired at prices around £21.50–£21.70 per share on 9 and 10 April 2026. Participants included CEO Luke Miels, who acquired 2,393.328 shares at £21.5039, and multiple presidents and senior officers, each completing a single, routine purchase.
GSK plc reported encouraging early-stage results for mocertatug rezetecan (Mo-Rez), a B7-H4-targeted antibody-drug conjugate, in difficult-to-treat gynaecological cancers. In the phase 1 BEHOLD-1 trial, Mo-Rez monotherapy achieved confirmed objective response rates of 62% in platinum-resistant ovarian cancer and 67% in recurrent or advanced endometrial cancer at the highest doses tested.
The safety profile was described as manageable: very few patients stopped treatment because of treatment-related side effects, and serious side effects were mainly blood-related, which is typical for this drug class. Interstitial lung disease or pneumonitis occurred in 3% of patients and was mild to moderate. The median duration of response had not yet been reached at this interim analysis, suggesting responses may be durable but follow-up is ongoing.
On the back of these data, GSK plans to advance Mo-Rez into five pivotal global phase III trials in 2026 across ovarian and endometrial cancer settings, including earlier-line and maintenance use. This programme underscores GSK’s broader oncology strategy focused on antibody-drug conjugates and women’s cancers.
GSK plc reports that on 10 April 2026 it repurchased 325,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. The shares were bought at prices between 2,157.00p and 2,196.00p, with a volume-weighted average price of 2,182.28p, and will be held as treasury shares.
Since 17 February 2026, GSK has bought 18,221,521 ordinary shares. Following this latest transaction, it holds 258,112,615 shares in treasury and has 4,058,078,154 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.36% of voting rights, a figure shareholders can use when assessing notification thresholds.
GSK plc reports routine insider share acquisitions linked to its Share Reward Plan. Several senior executives and persons closely associated with them acquired small numbers of GSK ordinary shares of 31¼ pence each through the automatic reinvestment of dividends paid on 9 April 2026.
Transactions were executed on the London Stock Exchange at prices of £21.3387 and £21.5039 per share, with individual amounts ranging from low single-digit shares to just over 1,000 shares. These acquisitions reflect dividend reinvestment rather than open-market buying decisions.
GSK plc reports that on 09 April 2026 it repurchased 330,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing buyback programme. The volume-weighted average price was 2,139.38p, with prices between 2,124.00p and 2,158.00p per share.
The repurchased shares will be held as Treasury shares. Since 17 February 2026, GSK has bought 17,896,521 ordinary shares. After this transaction, it holds 257,787,615 ordinary shares in treasury and has 4,058,396,834 ordinary shares in issue, all carrying voting rights.
GSK states that the total number of voting rights is 4,058,396,834 and confirms that, following this purchase, ordinary shares held in treasury represent 6.35% of its voting rights.
GSK plc reported that President Maya Martinez-Davis acquired notional American Depositary Shares through her GSK Executive Supplemental Savings Plan account. The plan transaction on 2026-04-07 involved 8.551 ADS at a price of $55.8400 per ADS on the New York Stock Exchange.